Brigatinib, sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc.[3] Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.[medical citation needed]
Brigatinib could overcome resistance to osimertinib conferred by the EGFR C797S mutation if it is combined with an anti-EGFR antibody such as cetuximab or panitumumab.[4]
^"Summary Basis of Decision (SBD) for Alunbrig". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^"Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.
^Huang WS, Liu S, Zou D, Thomas M, Wang Y, Zhou T, et al. (May 2016). "Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase". Journal of Medicinal Chemistry. 59 (10): 4948–4964. doi:10.1021/acs.jmedchem.6b00306. PMID 27144831.
^Uchibori K, Inase N, Araki M, Kamada M, Sato S, Okuno Y, et al. (March 2017). "Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer". Nature Communications. 8: 14768. Bibcode:2017NatCo...814768U. doi:10.1038/ncomms14768. PMC 5355811. PMID 28287083.
Brigatinib, sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc...
resistant to or unable to tolerate other tyrosine kinase inhibitors, and brigatinib, a lung cancer drug which has completed its registration trial in ALK...
"EGFR inhibitors", EGFRi), including gefitinib, erlotinib, afatinib, brigatinib and icotinib for lung cancer, and cetuximab for colon cancer. More recently...
phase 3 ALEX trial comparing it with crizotinib. Ariad's and Takeda's brigatinib (also an inhibitor of mutated EGFR) was the latest second-generation inhibitor...
treated with ALK inhibitors crizotinib, or its successors alectinib, brigatinib, and ceritinib. Those treated with ALK inhibitors who relapse can then...
Brigatinib, a lung cancer treatment and AP32788 (now known as TAK788), a new medicine for lung cancer with novel mutated genetic targets. Brigatinib is...
Global Information
